Revenue Recognition

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue Recognition

15. Revenue Recognition

The following table provides information about disaggregated revenue by product and services:

	Year Ended December 31,
	2024		2023
Product sales, net	$	35,336	$	13,149
Services		5,140		5,441
License, royalty and other		13,744		4,181
Total revenues	$	54,220	$	22,771

Net revenues include: (i) sales of biomaterial products, including Biovance, Biovance 3L, Rebound, Interfyl, and CentaFlex, of which our direct sales are included in Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.

The following table provides changes in deferred revenue from contract liabilities:

	2024			2023
Balance at January 1	$	6,020		$	4,492
Deferral of revenue (1)		5,731			6,266
Recognition of unearned revenue (2)		(5,496	)		(4,738	)
Balance at December 31	$	6,255		$	6,020

(1)	Deferral of revenue includes $5,061 in 2024 resulting from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.
(2)	Recognition of unearned revenue includes $2,561 that was included in the beginning deferred revenue balance at January 1, 2024.